Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily Biotech Top 5 Bull 2X ETF

36.95
-0.9597-2.53%
Post-market: 36.950.00000.00%16:10 EDT
Volume:799
Turnover:29.62K
Market Cap:2.77M
PE:- -
High:37.04
Open:37.04
Low:36.95
Close:37.91
52wk High:45.88
52wk Low:25.71
Shares:75.00K
Float Shares:75.00K
Volume Ratio:0.71
T/O Rate:1.07%
Dividend:0.76
Dividend Rate:2.07%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know

TradingKey
·
Yesterday

NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01

Reuters
·
Yesterday

Regeneron price target raised to $930 from $870 at Jefferies

TIPRANKS
·
Yesterday

Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth

TIPRANKS
·
Yesterday

Expanded Sanofi agreement particularly favorable for Regeneron, says TD Cowen

TIPRANKS
·
Yesterday

Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall

Dow Jones
·
Yesterday

Regeneron says COURAGE trial confirms trevogrumab prevents muscle loss

TIPRANKS
·
Oct 01

Regeneron Pharmaceuticals, - 9-Month Median Duration of Response Observed at 800 Mg Ubamatamab Dose

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Ubamatamab Shows 73% Objective Response Rate and 11-Month Median Pfs in Lgsoc Patients

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Serious Teaes Grade 3+ in 21% of Lgsoc Patients; Traes in 74%; Neutropenia, Anemia, Elevated Liver Enzymes

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - to Advance Ubamatamab into Confirmatory Phase 3 Trial for Lgsoc

THOMSON REUTERS
·
Oct 01

Ubamatamab (Muc16xcd3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (Lgsoc)

THOMSON REUTERS
·
Oct 01

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

GlobeNewswire
·
Oct 01

Regeneron Says Phase 2 Courage Trial Shows Trevogrumab Preserves Lean Mass During Semaglutide Weight Loss

Reuters
·
Oct 01

Regeneron Pharmaceuticals, - Lower Doses of Trevogrumab Well Tolerated with 77% Experiencing at Least One Adverse Event

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Plans Phase 2 Trial of Trevogrumab with Glp-1 Therapies in Older Adults

THOMSON REUTERS
·
Oct 01

Phase 2 Courage Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During Glp-1 Receptor Agonist-Induced Weight Loss

THOMSON REUTERS
·
Oct 01

Regeneron Pharmaceuticals, - Trevogrumab Prevents 70% of Muscle Loss Associated with Semaglutide Treatment

THOMSON REUTERS
·
Oct 01

Gilead Sciences Announces Dividend of R$ 0.2394442440 Per Unit for Brgildbdr 000

Reuters
·
Oct 01

Regeneron Exec Says Co Eligible to Receive $1 Bln in Potential Milestone Payment with the Start of the First Late-Stage Trial as Part of the Deal -Conf Call

THOMSON REUTERS
·
Oct 01